Coverage of IDWeek 2014 coverage of IDWeek 2014, October 8-12, in Philadelphia.

Conference highlights include the HIV cascade of care, experimental antiretroviral therapies, interferon-free hepatitis C treatment, and news about other infectious diseases including Ebola virus and enterovirus D68.

Full listing of coverage by topic

IDWeek 2014 website



October 15 is National Latino AIDS Awareness Day

October 15 is National Latino AIDS Awareness Day(NLAAD), an opportunity to raise awareness about HIV/AIDS among Latino and Hispanic people in the U.S. According to the Centers for Disease Control and Prevention (CDC), while Latinos/Hispanics make up approximately 16% of the total U.S. population, they accounted for about 21% of all new HIV infections in 2010. The incidence rate for Latinos is about 3 times higher than that of whites, with a majority of cases occurring among young men who have sex with men.


IDWeek 2014: Behavioral and Financial Incentives May Improve HIV Treatment Outcomes

While making medications free can remove barriers to access for individuals who cannot pay for treatment, data suggest that for most people accessing care in industrialized countries, "making medications available for free or low cost will not solve problems with medication non-adherence," according to a presentation by Kevin Volpp from the University of Pennsylvania last week at IDWeek 2014 in Philadelphia.


IDWeek 2014: Efavirenz Not Linked to Suicide in Analysis of Insurance Records

The non-nucleoside reverse transcriptase inhibitor efavirenz (Sustiva, also in the Atripla single-tablet regimen) was not associated with a higher rate of suicidal thoughts or attempts in an analysis conducted by manufacturer Bristol-Myers Squibb (BMS), researchers reported at the 2014 IDWeek meeting last week in Philadelphia.


Entire Female Reproductive Tract May Be Susceptible to HIV Infection

HIV may infect T-cells throughout the female reproductive tract including the vagina, ovaries, and surrounding lymph nodes -- not only the cervix, which has been the focus of most previous research, according to a study of macaque monkeys published in the October 9 edition of PLoS Pathogens.


IDWeek 2014: Complera Matches Atripla for Women Starting HIV Treatment

The Complera (rilpivirine/tenofovir/emtricitabine) single-tablet regimen worked as well as Atripla (efavirenz/tenofovir/emtricitabine) for treatment-naive women and was somewhat better tolerated in the open-label STaR trial, according to a report at the IDWeek 2014 meeting last week in Philadelphia.


IDWeek 2014: HIV Attachment Inhibitor BMS-663068 Works Well Across Patient Subgroups

An experimental attachment inhibitor that binds to the surface of the HIV envelope and prevents it from attaching to and entering CD4 T-cells demonstrated good virological response rates and tolerability regardless of age, sex, or race/ethnicity, according to research presented at IDWeek 2014, now underway in Philadelphia.